Case number 1:22-cv-01071
Merck Sharp & Dohme LLC. v. Prinston Pharmaceutical Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 17, 2023 | 11 | PROPOSED Consent Judgment as to Defendant Prinston Pharmaceuticals Inc., by Merck Sharp & Dohme LLC., Merck Sharp & Dohme LLC. (Silver, Daniel) Modified on 2/17/2023 (nms). (Entered: 02/17/2023) (3) |
| Feb 17, 2023 | 12 | CONSENT JUDGMENT as to Defendant Prinston Pharmaceuticals Inc.. Signed by Judge Richard G. Andrews on 2/17/2023. Associated Cases: 1:19-md-02902-RGA, 1:22-cv-01071-RGA(nms) (Entered: 02/17/2023) (3) |
| Feb 17, 2023 | 13 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,326,708. (Attachments: # 1 Consent Judgment)(nms) (Entered: 02/17/2023) (Main Document) (1) |
| Feb 17, 2023 | 13 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,326,708. (Attachments: # 1 Consent Judgment)(nms) (Entered: 02/17/2023) (Consent Judgment) (3) |
| Nov 9, 2022 | 9 | ANSWER to 1 Complaint and Affirmative Defenses, by Prinston Pharmaceutical Inc..(Gattuso, Dominick) Modified on 11/9/2022 (nms). (Entered: 11/09/2022) (16) |
| Nov 9, 2022 | 10 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Zhejiang Huahai Pharmaceutical Co., Ltd. for Prinston Pharmaceutical Inc. filed by Prinston Pharmaceutical Inc.. (Gattuso, Dominick) (Entered: 11/09/2022) (2) |
| Oct 7, 2022 | 8 | STIPULATION and Order to Extend Time - filed by Prinston Pharmaceutical Inc.. (Gattuso, Dominick) Modified on 10/7/2022 (nms). (Entered: 10/07/2022) (2) |
| Sep 20, 2022 | 7 | SUMMONS Returned Executed by Merck Sharp & Dohme LLC..Prinston Pharmaceutical Inc. served on 9/19/2022, answer due 10/11/2022. (Silver, Daniel) (Entered: 09/20/2022) (2) |
| Aug 15, 2022 | 1 | Complaint* (1) |
| Aug 15, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) (Entered: 08/15/2022) (3) |
| Aug 15, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: July 1, 2022. Date of Expiration of Patent: November 24, 2026.Thirty Month Stay Deadline: 1/1/2025. (mpb) (Entered: 08/15/2022) (2) |
| Aug 15, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,326,708. (mpb) (Entered: 08/15/2022) (1) |
| Aug 15, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Merck & Co., Inc. for Merck Sharp & Dohme LLC. filed by Merck Sharp & Dohme LLC.. (mpb) (Entered: 08/15/2022) (2) |
| Aug 15, 2022 | 6 | Summons Issued as to Prinston Pharmaceutical Inc. on 8/15/2022. (mpb) (Entered: 08/15/2022) (2) |
